Emerging and re-emerging infections at the turn of the millennium

Haemophilia

Volumn 16, Issue SUPPL. 1, 2010, Pages 7-12

  Zanetti, A R ^a   Zappa, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Emerging; Infections; Prion; Re emerging pathogens; Virus

Indexed keywords

PRION PROTEIN;

ARTICLE; BLEEDING DISORDER; BLOOD TRANSFUSION; CHIKUNGUNYA ALPHAVIRUS; COMMUNICABLE DISEASE; DENGUE VIRUS; DISEASE CARRIER; DISEASE TRANSMISSION; EBOLA VIRUS; GENETIC VARIABILITY; GLOBAL CHANGE; GREENHOUSE EFFECT; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MARBURG VIRUS; NONHUMAN; PANDEMIC; PRION DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANIMALS; COMMUNICABLE DISEASES, EMERGING; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; MALE; PRION DISEASES; VIRUS DISEASES; WORLD HEALTH;

EID: 73949137582     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02174.x     Document Type: Article

References (40)

1. Khan IA. Plague: the dreadful visitation occupying the human mind for centuries. Trans R Soc Trop Med Hyg 2004, 98:270-7.
2. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430:242-9.
3. Morens DM, Fauci AS. The 1918 influenza pandemic. J Infect Dis 2007, 195:1018-28.
4. Severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 2003, 78:89-96.
5. Cohen ML. Changing patterns of infectious disease. Nature 2000, 406:762-7.
6. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001, 32:675-85.
7. Report: the global burden of disease. 2004, http://www.who.int/entity/healthinfo/global_burden_disease/2004_report_update/en/index.html, update. Available at: Accessed 2004
8. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004, 10:S70-6.
9. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 2004, 10:1177-85.
10. Mayer JD. Geography, ecology and emerging infectious diseases. Soc Sci Med 2000, 50:937-52.
11. Infectious diseases update: outbreak, hantavirus infection - southwestern United States, 1993. JAMA 1993, 270:25.
12. Caldwell JD. Hantavirus cardiopulmonary syndrome. 2009, http://emedicine.medscape.com, Available at: Accessed 29 January 2009
13. Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006, 4:23-35.
14. Jones KE, Patel NG, Levy MA. Global trends in emerging infectious diseases. Nature 2008, 451:990-3.
15. Webby R, Hoffmann E, Webster R. Molecular constraints to interspecies transmission of viral pathogens. Nat Med 2004, 10:S77-S81.
16. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. The origins of acquired immune deficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci 2001, 356:867-76.
17. AIDS EPIDEMIC UPDATE, December 2009. http://data.unaids.org/pub/Report/2009/2009_epidemic_update/_en.pdf, Available at:
18. Shi Z, Hu Z. A review of studies on animaI reservoirs of the SARS coronavirus. Virus Res 2008, 133:74-87.
19. Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS). 2003, http://www.who.int/csr/sars/country/table2004_04_21/en/index.html, Available at: Accessed: 21 April 2004
20. Bowen ETW, Platt GS, Lloyd G, Baskerville A, Harris WJ, Vella EC. Viral haemorrhagic fever in southern Sudan and northern Zaire: preliminary studies on the aetiological agent. Lancet 1977, 1:571-3.
21. Ebola haemorrhagic fever in imported Monkeys. Wkly Epidemiol Rec 1992, 67:142-3.
22. Kissling RE, Murphy FA, Henderson BE. Marburg virus. Ann N Y Acad Sci 1970, 174:932-45.
23. Monath TP. Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis 1999, 179:SI27-38.
24. Timen A, Koopmans MPG, Vossen ACTM. Response to imported case of Marburg hemorrhagic fever, the Netherlands. Emerg Infect Dis 2009, 15:1171-5.
25. Gubler DJ. Resurgent Vector-Borne Diseases as a Global Health Problem. Emerg Infect Dis 1998, 4:442-50.
26. Pealer LN, Marfin AA, Petersen LR. Transmission of Wet Nile Virus through blood transfusion- United States, 2002. N Engl J Med 2003, 349:1236-45.
27. Update: 'detection of West Nile virus in blood donations - United States, 2003'. Morb Mortal Wkly Rep 2003, 52:916-9.
28. Grazzini G, Liumbruno GM, Pupella S. West Nile virus in Italy: a further threat to blood safety, a further challenge to blood system. Blood Transfus 2008, 6:235-37.
29. Rezza G, Nicoletti L, Angelini R. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007, 370:1840-6.
30. Liumbruno GM, Calteri D, Petropulacos K. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 2008, 6:199-210.
31. De Jong JC, Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus: a master of metamorphosis. J Infect 2000, 40:218-28.
32. Cumulative number of confirmed human cases of Avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_08_11/en/index.html, Available at: Accessed: 11 August 2009
33. Peiris JSM, De Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007, 20:243-67.
34. Outbreak of swine-origin Influenza A (HINl) virus infection - Mexico, March-April 2009. Morb Mortal Wkly Rep 2009, 58:431-3.
35. Gallaher WR. Towards a sane and rational approach to management of influenza H1N1 2009. Virol J 2009, 6:51.
36. Van Everbroeck B, Pals P, Martin JJ, Cras P. Transmissible spongiform encephalopathies: the story of a pathogenic protein. Peptides 2002, 23:1351-9.
37. Llewelyn CA, Hewitt PE, Knight RS. Possible transmission of variant Creutzfeldt-Jacob disease by blood transfusion. Lancet 2004, 363:417-21.
38. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004, 264:527-9.
39. Signs of variant Creutzfeldt-Jakob disease in a patient with hemophilia: FVIII concentrates most likely cause. http://www.wfh.org/2/9/9_3_vCJD.htm, Available at: Accessed: 16 February 2009
40. Lee CA, Miller JLA, Petteway SR. Pathogen safety of manufacturing processes for biological products: special emphasis on Kogenate Bayer. Haemophilia 2002, 8:69.